One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Effect of Intravenous Fluid Treatment With a Balanced Solution vs 0.9% Saline Solution on Mortality in Critically Ill PatientsThe BaSICS Randomized Clinical Trial
Fernando G. Zampieri, MD, PhD1,2; Flávia R. Machado, MD, PhD2,3; Rodrigo S. Biondi, MD2,4; Flávio G. R. Freitas, MD, PhD2,5; Viviane C. Veiga, MD, PhD2,6; Rodrigo C. Figueiredo, MD7; Wilson J. Lovato, MD8; Cristina P. Amêndola, MD, PhD9; Ary Serpa-Neto, MD, PhD2,10; Jorge L. R. Paranhos, MD11; Marco A. V. Guedes, MD, PhD12; Eraldo A. Lúcio, MD, PhD13; Lúcio C. Oliveira-Júnior, MD14; Thiago C. Lisboa, MD, PhD2,15; Fábio H. Lacerda, MD16; Israel S. Maia, MD2,17; Cintia M. C. Grion, MD, PhD2,18; Murillo S. C. Assunção, MD, PhD10; Airton L. O. Manoel, MD, PhD19; João M. Silva-Junior, MD, PhD20; Péricles Duarte, MD21; Rafael M. Soares, PhD1; Tamiris A. Miranda, MSc1; Lucas M. de Lima, IT1; Rodrigo M. Gurgel, Biomed Sci1; Denise M. Paisani, PhD1; Thiago D. Corrêa, MD, PhD2,10; Luciano C. P. Azevedo, MD, PhD2,22; John A. Kellum, MD23; Lucas P. Damiani, MSc1; Nilton Brandão da Silva, MD, PhD24; Alexandre B. Cavalcanti, MD, PhD1,2; for the BaSICS investigators and the BRICNet members
doi : 10.1001/jama.2021.11684
JAMA. 2021;326(9):818-829
Intravenous fluids are used for almost all intensive care unit (ICU) patients. Clinical and laboratory studies have questioned whether specific fluid types result in improved outcomes, including mortality and acute kidney injury.
Effect of Slower vs Faster Intravenous Fluid Bolus Rates on Mortality in Critically Ill PatientsThe BaSICS Randomized Clinical Trial
Fernando G. Zampieri, MD, PhD1,2; Flávia R. Machado, MD, PhD2,3; Rodrigo S. Biondi, MD2,4; Flávio G. R. Freitas, MD, PhD2,5; Viviane C. Veiga, MD, PhD2,6; Rodrigo C. Figueiredo, MD7; Wilson J. Lovato, MD8; Cristina P. Amêndola, MD, PhD9; Murillo S. C. Assunção, MD, PhD10; Ary Serpa-Neto, MD, PhD2,10; Jorge L. R. Paranhos, MD11; José Andrade, MD12; Michele M. G. Godoy, MD, PhD13; Edson Romano, MD, PhD14; Felipe Dal Pizzol, MD, PhD2,15; Emerson B. Silva, MD16; Miqueias M. L. Silva, MD, MSc17; Miriam C. V. Machado, MD18; Luiz Marcelo S. Malbouisson, MD, PhD19; Airton L. O. Manoel, MD, PhD20; Marlus M. Thompson, MD21; Lanese M. Figueiredo, MD, MSc22; Rafael M. Soares, PhD1; Tamiris A. Miranda, MSc1; Lucas M. de Lima1; Eliana V. Santucci,1; Thiago D. Corrêa, MD, PhD2,10; Luciano C. P. Azevedo, MD, PhD2,23; John A. Kellum, MD24; Lucas P. Damiani, MSc1; Nilton B. Silva, MD, PhD25; Alexandre B. Cavalcanti, MD, PhD1,2; for the BaSICS investigators and the BRICNet members
doi : 10.1001/jama.2021.11444
JAMA. 2021;326(9):830-838
Slower intravenous fluid infusion rates could reduce the formation of tissue edema and organ dysfunction in critically ill patients; however, there are no data to support different infusion rates during fluid challenges for important outcomes such as mortality.
Effect of School Integrated Pest Management or Classroom Air Filter Purifiers on Asthma Symptoms in Students With Active AsthmaA Randomized Clinical Trial
Wanda Phipatanakul, MD, MS1,2; Petros Koutrakis, PhD3; Brent A. Coull, MD, PhD3,4; Carter R. Petty, MA5; Jonathan M. Gaffin, MD, MMSc2,6; William J. Sheehan, MD1,7; Peggy S. Lai, MD, MPH2,8; Lisa M. Bartnikas, MD1,2; Choong-Min Kang, PhD3; Jack M. Wolfson, PhD3; Mihail Samnaliev, PhD5; Amparito Cunningham, MD, MPH1; Sachin N. Baxi, MD1,2; Perdita Permaul, MD9,10; Marissa Hauptman, MD, MPH2,11; Michelle Trivedi, MD, MPH12; Margee Louisias, MD, MPH13; Liming Liang, PhD4; Peter S. Thorne, PhD, MS14; Nervana Metwali, PhD14; Gary Adamkiewicz, PhD, MPH3; Elliot Israel, MD3,15; Andrea A. Baccarelli, MD, ScD16; Diane R. Gold, MD, MPH2,3,17; for the School Inner-City Asthma Intervention study team
doi : 10.1001/jama.2021.11559
JAMA. 2021;326(9):839-850
School and classroom allergens and particles are associated with asthma morbidity, but the benefit of environmental remediation is not known.
Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine Immune Serum Samples
Timothy A. Bates, BSc1; Hans C. Leier, BA1; Zoe L. Lyski, MS1; James R. Goodman, MD, PhD2; Marcel E. Curlin, MD3; William B. Messer, MD, PhD1; Fikadu G. Tafesse, PhD1
doi : 10.1001/jama.2021.11656
JAMA. 2021;326(9):868-869
Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents
Thomas Radtke, PhD1; Agne Ulyte, MD, PhD1; Milo A. Puhan, MD, PhD1; Susi Kriemler, MD1
doi : 10.1001/jama.2021.11880
JAMA. 2021;326(9):869-871
Aligning Payments, Services, and Quality in Primary Care
John H. Wasson, MD1; Harold C. Sox, MD2; Harold D. Miller3
doi : 10.1001/jama.2021.12775
JAMA. 2021;326(9):805-806
Enforcement of the Physician Payments Sunshine ActTrust and Verify
Eli Y. Adashi, MD, MS1; I. Glenn Cohen, JD2
doi : 10.1001/jama.2021.13156
JAMA. 2021;326(9):807-808
Cancer as a Global Health Priority
Satish Gopal, MD1; Norman E. Sharpless, MD1
doi : 10.1001/jama.2021.12778
JAMA. 2021;326(9):809-810
Drifting Over the HorizonNavigating the End-of-Life Journey
David Allan Gruenewald, MD1,2
doi : 10.1001/jama.2021.14031
JAMA. 2021;326(9):811-812
Does Crystalloid Composition or Rate of Fluid Administration Make a Difference When Resuscitating Patients in the ICU?
Michael J. Connor Jr, MD1,2; Craig M. Coopersmith, MD2,3
doi : 10.1001/jama.2021.11119
JAMA. 2021;326(9):813-815
School Classrooms as Targets to Reduce Allergens and Improve Asthma
William W. Busse, MD1; Daniel J. Jackson, MD2
doi : 10.1001/jama.2021.12322
JAMA. 2021;326(9):816-817
Pancreatic CancerA Review
Wungki Park, MD1,2,3,4; Akhil Chawla, MD5,6; Eileen M. O’Reilly, MD1,2,3
doi : 10.1001/jama.2021.13027
JAMA. 2021;326(9):851-862
Pancreatic ductal adenocarcinoma (PDAC) is a relatively uncommon cancer, with approximately 60?430 new diagnoses expected in 2021 in the US. The incidence of PDAC is increasing by 0.5% to 1.0% per year, and it is projected to become the second-leading cause of cancer-related mortality by 2030.
Cognitive Decline Associated With Anesthesia and Surgery in Older Patients
Susana Vacas, MD, PhD1; Daniel J. Cole, MD1; Maxime Cannesson, MD, PhD1
doi : 10.1001/jama.2021.4773
JAMA. 2021;326(9):863-864
Inflammatory Myositis in a Patient With Melanoma
Mithu Maheswaranathan, MD1; Michel G. Khouri, MD2; Sophia C. Weinmann, MD1
doi : 10.1001/jama.2021.9025
JAMA. 2021;326(9):865-866
Detecting Kids’ Broken Hearts—Cardiac Screening Advised During Well-Child Visits
Anita Slomski
doi : 10.1001/jama.2021.13323
JAMA. 2021;326(9):797-799
Most Fully Vaccinated Patients With Cancer Have SARS-CoV-2 Antibodies
Anita Slomski
doi : 10.1001/jama.2021.14707
JAMA. 2021;326(9):800
Covering Tracheostomies Reduces Viral Spread to Health Care Staff
Anita Slomski
doi : 10.1001/jama.2021.13454
JAMA. 2021;326(9):800
Novel Oral Drug Rapidly Treats Postpartum Depression
Anita Slomski
doi : 10.1001/jama.2021.14708
JAMA. 2021;326(9):800
Guidelines for Lipid-Lowering Therapy Intensification Rarely Followed
Anita Slomski
doi : 10.1001/jama.2021.14709
JAMA. 2021;326(9):800
First Interchangeable Biosimilar Insulin Drug Is Approved
Bridget M. Kuehn, MSJ
doi : 10.1001/jama.2021.14729
JAMA. 2021;326(9):801
Testing Monoclonal Antibodies for Rabies Prophylaxis
Bridget M. Kuehn, MSJ
doi : 10.1001/jama.2021.13757
JAMA. 2021;326(9):801
Developing Partnerships to Streamline Global Food Safety
Bridget M. Kuehn, MSJ
doi : 10.1001/jama.2021.14730
JAMA. 2021;326(9):801
Emoji for the Medical Community—Challenges and Opportunities
Debbie Lai, BA1; Jennifer 8. Lee, BA2; Shuhan He, MD3,4,5
doi : 10.1001/jama.2021.8409
JAMA. 2021;326(9):795-796
Variants of SARS-CoV-2
Adam S. Lauring, MD, PhD1; Preeti N. Malani, MD, MSJ1,2
doi : 10.1001/jama.2021.14181
JAMA. 2021;326(9):880
Age at Diabetes Onset and Subsequent Risk of Dementia
Rui Gao, MD, PhD1; Ruiqun Wang, MD1; Chan Chen, MD, PhD1
doi : 10.1001/jama.2021.10485
JAMA. 2021;326(9):871
Age at Diabetes Onset and Subsequent Risk of Dementia—Reply
Claudio Barbiellini Amidei, MD1; Aurore Fayosse, MSc1; Archana Singh-Manoux, PhD1
doi : 10.1001/jama.2021.10488
JAMA. 2021;326(9):871-872
Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs and Disease Flare in Patients With Rheumatoid Arthritis
Kenneth Frank Baker, PhD1; Arthur Grant Pratt, PhD1; John Dudley Isaacs, PhD1
doi : 10.1001/jama.2021.10648
JAMA. 2021;326(9):872-873
Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs and Disease Flare in Patients With Rheumatoid Arthritis—Reply
Siri Lillegraven, MD, MPH, PhD1; Nina Paulshus Sundlisæter, MD, PhD1; Espen A. Haavardsholm, MD, PhD1
doi : 10.1001/jama.2021.10651
JAMA. 2021;326(9):873
Incorrect Classification of Pharmaceutical Agent
doi : 10.1001/jama.2021.14278
JAMA. 2021;326(9):873
